Brooksville, Florida, United States, February 2025 – American Injectables, a leading contract development and manufacturing organization (CDMO) specializing in sterile injectables, has announced key leadership appointments to strengthen the company’s position for future growth. These changes come at a crucial time when the demand for domestic pharmaceutical manufacturing continues to rise.
Travis Allen, who has played a significant role in American Injectables’ growth since its inception, has been appointed as Chief Executive Officer and Board Director. Paul Campanelli, former CEO of Endo International and Par Pharmaceutical, will transition into the role of Executive Chairman, while Kimberlee Steele, Managing Director of North America at SHL Medical, joins as a Board Member.
“This transition is the result of a focused strategy years in the making,” said Travis Allen. “Having been part of American Injectables from the start, I’m proud to lead a team that works closely with customers—navigating complexity, ensuring reliability, and driving execution from clinical to commercial.”
With a Pharm.D. background, Allen brings a unique mix of scientific expertise, operational leadership, and business development acumen. He has led the expansion of sterile injectable capabilities, from business development in the 503B outsourcing space to founding and scaling a commercial sterile injectables facility. His technical and strategic industry expertise will drive continued innovation and ensure high-quality, domestically produced sterile injectables.
The leadership team is further strengthened by Campanelli’s sterile products expertise and Steele’s 25-year track record in pharmaceutical and medical device industries. Campanelli, who has served on the board since March 2024, will play a key role in governance and strategic oversight. Steele, a former leader at SHL Medical and Catalent, has deep experience across biologics, injectable drug products, and cell and gene therapy.
“American Injectables’ commitment to transparent partnership and customer focus aligns perfectly with where our industry needs to go,” said Kimberlee Steele, newly appointed Board Member. “I’m excited to help guide the company through its next phase of growth.”
Following its recent FDA approval, American Injectables is expanding its sterile injectable manufacturing capabilities. With these leadership transitions, the company is poised to accelerate growth, enhance operational excellence, and meet increasing industry demand while maintaining the highest quality standards.
About American Injectables
American Injectables is a privately held contract development and manufacturing organization (CDMO) specializing in ready-to-use glass and plastic vials and nested syringes. The company offers formulation optimization, analytical and stability services, and process engineering. Based in Florida, its state-of-the-art facilities serve both U.S. and global markets, offering flexible partnerships and priority timelines.
Read Also : Entering 2025, TA Leaders’ Success Built on More than Just Hiring, Says The Josh Bersin Company
People Analytics Teams Still Struggle to Deliver Business Impact, Warns The Josh Bersin Company
ESG and Women’s Leadership: Driving Sustainability and Inclusion
Learning and Development Trends for 2025: Shaping the Future of Workplace Learning
